Latigo Biotherapeutics Stock (NASDAQ:LTGO)
Previous Close
$22.48
52W Range
$17.22 - $25.93
50D Avg
$21.32
200D Avg
$21.32
Market Cap
$1.39B
Avg Vol (3M)
$373.07K
Beta
-
Div Yield
-
LTGO Company Profile
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.